Which Alzheimer’s Blood Test Is Most Accurate? Biomarkers Compared

When people begin researching Alzheimer’s screening, one question comes up quickly: Which Alzheimer’s blood test is the most accurate?

In recent years, blood-based testing has transformed how researchers evaluate memory health. Instead of relying solely on brain scans or spinal fluid tests, scientists can now measure biological signals in the bloodstream that may indicate changes associated with Alzheimer’s disease.

But not all Alzheimer’s blood tests measure the same thing. Different tests rely on different biomarkers, and those biomarkers vary in how closely they reflect Alzheimer’s disease itself.

Understanding how these biomarkers work can help you better interpret what today’s tests actually measure — and why some may provide clearer insight than others.

How Alzheimer’s Blood Tests Work

Alzheimer’s disease does not begin when memory symptoms appear. In many cases, biological changes in the brain start years before significant cognitive decline.

These changes can include:

• The buildup of amyloid plaques
• Abnormal forms of tau proteins
• Gradual damage to neurons

The Link Between Blood Biomarkers and Cognitive Changes

Researchers now know that some of these biological processes leave detectable traces in the bloodstream — or blood biomarkers.

Blood tests can measure these signals, allowing clinicians and researchers to estimate whether Alzheimer’s-related changes may be occurring in the brain.

In the context of Alzheimer’s disease, biomarkers can help identify whether specific neurological processes are occurring.

However, different biomarkers reflect different types of brain activity, which is why their accuracy for detecting Alzheimer’s can vary.

Why Alzheimer’s Blood Test Accuracy Depends on Biomarkers

When people ask about Alzheimer's blood test accuracy, the real question is often this: Which biomarker provides the clearest signal of Alzheimer’s disease before it progresses?

Modern blood tests generally rely on one of three biomarker strategies. Each approach provides useful information, but not all of them directly measure Alzheimer’s pathology.

Most of today’s tests that measure brain health rely on one of the following biomarker categories:

• General neurodegeneration markers
• Amyloid-related markers
• Tau-related markers

Understanding how these biomarkers differ is key to understanding how Alzheimer’s blood tests compare.

Biomarkers Commonly Used in Alzheimer’s Blood Tests

Several biomarkers are currently used in Alzheimer’s research and testing platforms.

Each measures a different aspect of your brain’s biology, which means each provides a different type of insight into neurological health.

Neurofilament Light (NfL)

Neurofilament light chain, often called NfL, is a protein released into the bloodstream when neurons are damaged.

Because of this, NfL is widely used as a general marker of neurodegeneration. When nerve cells are injured, fragments of these structural proteins can enter the blood.

However, one important limitation of NfL is that it is not specific to Alzheimer’s disease. NfL levels can rise in many neurological conditions, including:

• Alzheimer’s disease
• Parkinson’s disease
• Traumatic brain injury
• Multiple sclerosis

NfL ultimately indicates that something is affecting the brain, but it cannot identify Alzheimer’s disease on its own.

GFAP (Glial Fibrillary Acidic Protein)

Another biomarker sometimes used in brain health testing is GFAP.

GFAP reflects astrocyte activity, or cells in the brain that respond to injury or inflammation.

When the brain experiences stress or damage, these cells become more active, and GFAP levels can increase.

Like NfL, GFAP can provide useful information about neurological health. However, it also reflects general brain injury or inflammation, not Alzheimer’s disease specifically.

Because of this, GFAP is often included in broader brain health panels rather than used as a standalone Alzheimer’s biomarker.

Amyloid Beta (Aβ42/40 Ratio)

Amyloid beta proteins are closely associated with Alzheimer’s disease. In the brain, these proteins can accumulate and form plaques — a hallmark feature of Alzheimer’s pathology.

Some blood tests estimate amyloid plaque activity by measuring the ratio between two forms of amyloid beta, known as Aβ42 and Aβ40.

This ratio can provide insight into whether amyloid plaque accumulation may be occurring in the brain. Several clinical diagnostic tests rely on this approach.

However, measuring amyloid proteins in blood presents challenges. Blood levels can fluctuate and may not always reflect early disease activity as clearly as other biomarkers.

Phosphorylated Tau (p-tau181)

Tau proteins help stabilize the internal structure of neurons, or brain cells. In Alzheimer’s disease, tau proteins can become abnormally processed, contributing to the formation of neuron tangles in the brain.

One biomarker researchers have studied extensively is p-tau181.

Compared with markers like NfL or GFAP, p-tau181 is more closely associated with Alzheimer’s pathology. However, newer research suggests that another tau biomarker may provide an even stronger signal.

Why P-tau217 Is Emerging as the Most Accurate Alzheimer’s Blood Biomarker

In recent years, researchers have increasingly focused on p-tau217, a phosphorylated tau biomarker strongly associated with Alzheimer’s disease.

Studies have shown that p-tau217 levels in blood closely correlate with the biological processes that define Alzheimer’s pathology in the brain.

This makes p-tau217 particularly promising as a blood-based biomarker for detecting Alzheimer’s-related changes.

Research suggests p-tau217 offers several advantages compared with broader biomarkers:

• Strong correlation with amyloid and tau pathology in the brain
• High diagnostic accuracy in research studies
• Ability to detect Alzheimer’s-related changes earlier
• Greater specificity compared to general neurodegeneration markers

How Today’s Alzheimer’s Blood Tests Compare

As interest in blood testing for Alzheimer’s disease grows, more options are becoming available. However, not all tests are designed to answer the same question.

Some tests aim to measure overall brain health, while others attempt to estimate the likelihood of Alzheimer’s pathology more directly. Understanding this difference is key to evaluating accuracy.

Brain Health Panel Tests

Some consumer-focused platforms offer multi-biomarker panels that measure multiple neurological markers simultaneously.

These panels may include biomarkers such as:

• NfL
• GFAP
• amyloid markers
• tau markers

While this approach can provide a wide range of data, it is important to understand how these panels are structured.

Many of the included biomarkers reflect general neurological processes, such as inflammation or neuron damage. Even when tau markers are included, they are typically part of a broader panel rather than the primary focus.

Because of this, results from panel-based tests may be less specific to Alzheimer’s disease, making it more difficult to isolate the biological changes most closely tied to the condition.

Amyloid-Focused Diagnostic Tests

Other testing approaches focus on amyloid beta biomarkers, which are associated with plaque buildup in the brain.

These tests are often used in clinical settings to estimate whether amyloid pathology may be present, particularly in patients already experiencing cognitive symptoms.

However, amyloid-based measurements can be complex to interpret and may not always reflect the earliest disease-specific changes, especially in blood-based testing.

Tau-Focused Early Detection

A more targeted approach focuses on tau biomarkers, which are closely tied to the biological processes that drive Alzheimer’s disease.

Among these, p-tau217 has emerged as one of the most specific indicators of Alzheimer’s pathology, offering a clearer signal compared to broader or indirect biomarkers.

Rather than measuring general brain health or estimating plaque presence alone, this approach focuses on detecting changes directly associated with the disease.

How Neurogen’s Approach Focuses on p-tau217 Accuracy

At Neurogen, we center our screening process on brain-derived p-tau217, enabling us to focus specifically on biological changes originating in the brain. This distinction significantly improves our ability to pinpoint potential Alzheimer’s signs.

Many biomarkers used in broader testing panels can be influenced by multiple conditions or systemic factors, making it harder to isolate Alzheimer ’s-specific signals.

By measuring brain-derived p-tau217, we can focus more precisely on the processes most closely tied to Alzheimer’s pathology, without the same level of interference from unrelated neurological or inflammatory activity.

Rather than distributing attention across multiple biomarkers, our approach prioritizes the signal most directly associated with the disease itself.

We combine this targeted biomarker analysis with cognitive screening and expert evaluation to provide a more complete view of memory health.

Our process includes:

• Brain-derived p-tau217 biomarker analysis
• Cognitive screening assessments
• At-home blood collection
• Neurologist analysis and follow-up

Know Before It Shows: Taking a Proactive Approach to Memory Health

Alzheimer’s disease develops gradually over time. Because of this, understanding potential biological changes early can provide valuable opportunities for planning, monitoring, and proactive care.

At Neurogen, our goal is to make early insights into memory health more accessible for everyone.

By focusing on at-home testing of blood biomarkers such as p-tau217 and combining them with expert analysis, we aim to provide a clearer picture of neurological health.